Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Oxygenta Pharmaceutical Ltd (524636)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524636 NSE: Pharmaceuticals & Drugs | Small Cap | Oxygenta Pharma Share Price
₹65.64 10.94 (20.00%)
As on 11-Aug'26 16:59
Oxygenta Pharmaceutical Ltd (524636)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524636 NSE: Pharmaceuticals & Drugs | Small Cap | Oxygenta Pharma Share Price
₹65.64 10.94 (20.00%)
As on 11-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹202 Cr.
Current Price
₹65.6
52-Week Low / High
₹43 / 103
TTM EPS
₹-3.7
TTM Sales
₹135 Cr.
Book Value per Share
₹-12.1
P/E Ratio
0.00
Industry PE
53.3
Price to Book (P/B)
-4.52
In line with its 5-year historical median
Price to Sales (P/S)
1.50
Lower than its 5-year historical median
EV/EBITDA
-39.45
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Underperforms industry median
Return on Capital Employed (ROCE)
-33.53%
Underperforms industry median
Return on Assets (ROA)
-20.42%
Operating Profit Margin
-13.5%
Net Profit Margin
-15.55%
Gross Profit Margin
-17.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
3.37%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
56.54%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-82 Cr.
Equity
₹37 Cr.
Face Value
₹10
All Time Low / High
₹0.10 / 133.50
Check Before You Invest
Quality
Not GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Weak
Is Oxygenta Pharmaceutical Ltd a good quality company?
Oxygenta Pharmaceutical Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Oxygenta Pharmaceutical Ltd performance compare with that of its Peers?
Revenue growth of Oxygenta Pharmaceutical Ltd vs industry peers?
Oxygenta Pharmaceutical Ltd revenue CAGR is 16.77%, compared to the industry median CAGR of 5.68%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Oxygenta Pharmaceutical Ltd?
Promoters hold 56.54% of the Oxygenta Pharmaceutical Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Oxygenta Pharmaceutical Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 18.1% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Oxygenta Pharmaceutical Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0% | 0% | 3.2% | -50.3% | -41.7% | -32.9% | -33.5% | - |
| Value Creation Index ⓘ | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 8.2 | 12.9 | 20.5 | 13.7 | 52 | 60.5 | 31 | 39.6 | 109 | 113 | 135 |
| Sales YoY Gr. | - | 57.9% | 59.4% | -33.1% | 279.2% | 16.3% | -48.8% | 27.9% | 175.7% | 3.4% | - |
| Adj EPS ⓘ | -5.7 | -4.4 | -3.2 | -8.4 | 2.9 | -0 | -7.8 | -1.1 | -2.8 | -4.7 | -3.7 |
| YoY Gr. | - | NA | NA | NA | NA | -101.1% | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | -26.8 | -31.3 | -34.5 | -40.1 | -37.3 | -24.4 | -32.5 | -6.2 | -6.9 | -11.5 | -12.1 |
| Adj Net Profit ⓘ | -5.8 | -4.5 | -3.3 | -8.6 | 2.9 | -0 | -11.1 | -3.5 | -10.2 | -17.5 | -14 |
| Cash Flow from Ops. ⓘ | 0.5 | 1.3 | -7.8 | -2.6 | -1.6 | -1.7 | -1.6 | -13.1 | 2.8 | -27.8 | - |
| Debt/CF from Ops. ⓘ | 37 | 14.9 | -2.9 | -10.4 | -29.5 | -31 | -41.6 | -4.4 | 22 | -4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 33.9% | 16.8% | 53.9% | 3.4% | ||||
| Adj EPS ⓘ | NA | -210.6% | NA | NA | ||||
| BVPSⓘ | NA | NA | NA | NA | ||||
| Share Price | 19.6% | 25.9% | 18.3% | -33.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 23.7 | 15.3 | 9.7 | 22.5 | -7.4 | 0.1 | 27.4 | 10.6 | 44.7 | 51.3 | 31 |
| Op. Profit Mgn % ⓘ | -59.4 | -31.1 | -10 | -57.4 | 7.4 | 2.4 | -23 | -24.4 | -8.8 | -13.5 | -6 |
| Net Profit Mgn % ⓘ | -71.2 | -35.2 | -15.9 | -62.5 | 5.6 | -0.1 | -35.7 | -8.9 | -9.4 | -15.5 | -10.1 |
| Debt to Equity ⓘ | -0.7 | -0.6 | -0.6 | -0.7 | -1.3 | -1.5 | -1.5 | -2.8 | -2.4 | -2.6 | - |
| Working Cap Days ⓘ | 290 | 151 | 122 | 216 | 82 | 82 | 217 | 235 | 96 | 137 | 105 |
| Cash Conv. Cycle ⓘ | -229 | -154 | -75 | -14 | -11 | -0 | 52 | 26 | -0 | -1 | -131 |
Valuation of Oxygenta Pharma - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 |
| Operating Expenses ⓘ + | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 |
| Operating Profit ⓘ | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 |
| Operating Profit Margin (%) | -59.4% | -31.1% | -10.0% | -57.4% | 7.4% | 2.4% | -23.0% | -24.5% | -9.0% | -13.6% |
| Other Income ⓘ + | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 |
| Profit Before Tax ⓘ | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -14 | -22 |
| Tax ⓘ | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -10 | -4 | -5 |
| Profit After Tax | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 |
| PAT Margin (%) | -71.2% | -35.2% | -15.9% | -42.2% | 5.6% | -1.0% | -37.3% | -8.8% | -9.4% | -15.6% |
| Adjusted EPS (₹) | -5.7 | -4.4 | -3.2 | -5.7 | 2.9 | -0.4 | -8.2 | -1.0 | -2.8 | -4.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | -27 | -32 | -35 | -41 | -38 | -35 | -46 | -21 | -26 | -43 | |
| Debt + | 18 | 18 | 21 | 26 | 48 | 52 | 67 | 56 | 61 | 107 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 9 | 11 | 9 | 8 | 14 | 6 | 24 | 23 | 30 | 49 | |
| Others Liabilities ⓘ | 19 | 20 | 26 | 26 | 10 | 7 | 9 | -4 | 4 | -11 | |
| Total Liabilities ⓘ | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 54 | 70 | 102 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 2 | 2 | 5 | 4 | 12 | 7 | 12 | 14 | 21 | 29 | |
| Trade Receivables | 1 | 0 | 1 | 0 | 2 | 2 | 10 | 7 | 5 | 10 | |
| Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | |
| Others Assets ⓘ | 3 | 3 | 3 | 2 | 3 | 2 | 4 | 4 | 7 | 13 | |
| Total Assets ⓘ | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 54 | 70 | 102 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Cash Flow From Investing Activity ⓘ + | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Cash Flow From Financing Activity ⓘ + | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net Cash Flow ⓘ | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| ROCE (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover Ratio | 0.42 | 0.71 | 1.08 | 0.69 | 1.98 | 1.86 | 0.73 | 0.73 | 1.76 | 1.31 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | -0.67 | N/A | N/A | N/A | N/A | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 52.50 | 19 | 8.80 | 12.50 | 7.10 | 9.60 | 69.10 | 80.70 | 20.80 | 24.40 |
| Inventory Days | 62.90 | 48.80 | 61.30 | 127.50 | 57.40 | 58.50 | 111.80 | 117 | 57.20 | 80.70 |
| Payable Days | 790.10 | 367.70 | 223.70 | 199.80 | 109.10 | 78.30 | 229.90 | 254 | 99.70 | 140.40 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Oxygenta Pharmaceutical Ltd FAQs
The current trading price of Oxygenta Pharma on 11-Aug-2026 16:59 is ₹65.64.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Aug-2026 the market cap of Oxygenta Pharma stood at ₹202.3 Cr
The latest P/E ratio of Oxygenta Pharma as of 10-Aug-2026 is 0.00.
The latest P/B ratio of Oxygenta Pharma as of 10-Aug-2026 is -4.52.
The 52-week high of Oxygenta Pharma is ₹102.7 and the 52-week low is ₹43.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Oxygenta Pharma is ₹135 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Oxygenta Pharmaceutical Ltd is a below average quality company.
The key valuation ratios of Oxygenta Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Oxygenta Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Oxygenta Pharmaceutical Ltd
SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.
A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.
Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.
The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
